Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.67 |
| ▸ | ACACA | Q13085 | 2/20 | 0.67 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.54 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CRYAB | P02511 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HMGCR | P04035 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CRYAA | P02489 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclolaudenol (24S) SCHEMBL3191608 | 1.00 | ACLY (0.67) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL15662610 | 0.90 | ACLY (0.66) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL17057009 | 0.90 | ACLY (0.66) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| Polysthicol (24S) SCHEMBL29374019 | 0.89 | ACLY (0.65) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL3479596 | 0.87 | ACLY (0.65) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL3479594 | 0.87 | ACLY (0.65) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL29510985 | 0.87 | ACLY (0.67) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL12634185 | 0.87 | ACLY (0.67) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13420288 | 0.86 | ACLY (0.70) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL14520017 | 0.86 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2641475-B1 | OIL OR FAT COMPOSITION | KAO CORP (JP) | 2018-03-28 | — | — | EP | claimed |
| US-20160184232-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.) | 2016-06-30 | — | — | US | claimed |
| US-20150306225-A1 | Compositions for Delivering Drugs with Low Water Solubility | Juntech Pharmaceuticals L.L.C. | 2015-10-29 | — | — | US | claimed |
| CN-103402499-A | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | MALLINCKRODT LLC | 2013-11-20 | — | — | CN | claimed |
| US-20130273153-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2013-10-17 | — | — | US | claimed |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-11-24 | — | — | US | claimed |
| WO-2011087765-A2 | METHODS OF PRODUCING STABILIZED SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT INC. (US) | 2011-07-21 | — | — | WO | claimed |
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-06-23 | — | — | US | claimed |
| WO-2011041470-A2 | SUSTAINED-RELEASE OPIATE AND OPIATE DERIVATIVE COMPOSITIONS | MALLINCKRODT INC. (US) | 2011-04-07 | — | — | WO | claimed |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | MALLINCKRODT INC. (US) | 2011-03-31 | — | — | US | claimed |
| CN-1709275-A | Use of flavone substance or triterpene compound for treating thyreoidism | CHEN CHEN (CN) | 2005-12-21 | — | — | CN | claimed |
| US-4748161-A | Triterpenyl esters of organic acids and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1988-05-31 | — | — | US | claimed |
| CN-85109752-A | Preparation triterpenoid organic acid ester and the method that contains the hypolipidemic agents of this compounds | — | 1986-12-17 | — | — | CN | claimed |
| EP-0166542-A2 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | claimed |
| US-4393044-A | HIGH RESISTANCE TO HYDROLYSIS | THE NISSHIN OIL MILLS LIMITED (JP) | 1983-07-12 | — | — | US | claimed |
| JP-58116415-A | — | — | None | — | — | JP | disclosed |
| CN-118475257-A | Oral compositions and methods for inhibiting bitterness from ergothioneine and odor from cereal oils or gamma-oryzanol | 三得利控股株式会社 | 2024-08-09 | — | — | CN | disclosed |
| EP-0166542-A2 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | disclosed |
| US-4393044-A | HIGH RESISTANCE TO HYDROLYSIS | THE NISSHIN OIL MILLS LIMITED (JP) | 1983-07-12 | — | — | US | disclosed |
| JP-S58116415-A | USING METHOD OF CHOLESTEROL REDUCING AGENT | RIYOUSHIYOKU KENKYUKAI | 1983-07-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | ACLY 4184/4885ACACA 4069/4885PTPN11 2636/4885 |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | ACLY 4184/4885ACACA 4069/4885PTPN11 2636/4885 |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | OPRL1, OPRK1, OPRM1 | ACLY 2086/4885ACACA 2526/4885PTPN11 3190/4885 |
| US-20130273153-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | ACLY 4184/4885ACACA 4069/4885PTPN11 2636/4885 |
| US-20160184232-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | ACLY 4184/4885ACACA 4069/4885PTPN11 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.